6-K 1 agmb-20260806x6k.htm 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2026

Commission File Number: 001-43098

AgomAb Therapeutics NV

Posthoflei 1/6

2600 Antwerpen

Belgium

Tel: +32 3 318 91 70

(Address, Including Zip Code, and Telephone Number,

Including Area Code, of Registrant’s Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On August 6, 2026, AgomAb Therapeutics NV (the “Company”) issued a press release titled, “Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook,” announcing the Company’s results for the period ended June 30, 2026 and providing a business update. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference.

The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Mr. Tim Knotnerus and Mr. Pierre Kemula included in Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on Form S-8 (File No. 333-294220).

INDEX TO EXHIBITS

Number		Description

99.1		Press Release of AgomAb Therapeutics NV dated August 6, 2026, announcing the Company’s results for the six months ended June 30, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	AgomAb Therapeutics NV

Date: August 6, 2026	By:	/s/ Tim Knotnerus
		Tim Knotnerus
		Chief Executive Officer